NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free NLTX Stock Alerts $32.50 -0.71 (-2.14%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$32.27▼$34.6750-Day Range$13.96▼$50.9052-Week Range$2.03▼$14.36Volume28,093 shsAverage Volume50,104 shsMarket Capitalization$305.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Neoleukin Therapeutics alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Neoleukin Therapeutics Stock (NASDAQ:NLTX)Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More NLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLTX Stock News HeadlinesDecember 20, 2023 | finance.yahoo.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. December 4, 2023 | benzinga.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesOctober 5, 2023 | markets.businessinsider.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…September 26, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 18, 2023 | benzinga.comNeoleukin Therapeutics Recent Insider ActivityMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. August 18, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXJuly 28, 2023 | finance.yahoo.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 26, 2023 | benzinga.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 24, 2023 | 247wallst.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 19, 2023 | markets.businessinsider.comNeurogene, Neoleukin Announce Planned MergerJuly 18, 2023 | msn.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | benzinga.comNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | msn.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | marketwatch.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | technews.tmcnet.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | finance.yahoo.comNeurogene and Neoleukin Announce Definitive Merger AgreementMay 23, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 9, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)April 7, 2023 | bizjournals.comNeoleukin Therapeutics promotes general counsel to interim CEOSee More Headlines Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.22% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio15.33 Quick Ratio15.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book2.93Miscellaneous Outstanding Shares9,398,000Free Float9,250,000Market Cap$305.44 million OptionableOptionable Beta1.11 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Donna M. Cochener-Metcalfe J.D. (Age 48)General Counsel, Interim CEO & Corporate Secretary Comp: $403.75kDr. David Baker M.D.Ph.D., Co-FounderMr. Sean Michael Smith (Age 37)Interim Chief Financial Officer Key CompetitorsVanda PharmaceuticalsNASDAQ:VNDACorMedixNASDAQ:CRMDOrganogenesisNASDAQ:ORGOKamadaNASDAQ:KMDAUroGen PharmaNASDAQ:URGNView All CompetitorsInsidersBros. Advisors Lp BakerBought 8,347 shares on 8/17/2023Total: $115,188.60 ($13.80/share)Bros. Advisors Lp BakerBought 94,440 shares on 8/15/2023Total: $1.19 M ($12.60/share)Sean Michael SmithSold 66 sharesTotal: $818.40 ($12.40/share)View All Insider Transactions NLTX Stock Analysis - Frequently Asked Questions How have NLTX shares performed in 2024? Neoleukin Therapeutics' stock was trading at $19.38 on January 1st, 2024. Since then, NLTX shares have increased by 67.7% and is now trading at $32.50. View the best growth stocks for 2024 here. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) EPS for the quarter, meeting the consensus estimate of ($5.60). When did Neoleukin Therapeutics' stock split? Neoleukin Therapeutics's stock reverse split before market open on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD). How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NLTX) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
